SCHEMBL26213675

SCHEMBL26213675

O=S(=O)(NCCCl)N1CCC(c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.51
▸ MMP2 P08253 1/20 0.45
▸ MMP13 P45452 1/20 0.45
▸ USP5 P45974 8/20 0.44
▸ CARM1 Q86X55 1/20 0.44
▸ PRMT6 Q96LA8 1/20 0.44
▸ MMP3 P08254 2/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.43
▸ HSD11B1 P28845 1/20 0.43
▸ MCL1 Q07820 1/20 0.43
▸ BCL2A1 Q16548 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SLC18A3 Q16572 1/20 0.41
▸ DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26213672 0.82 ALDH1A1 (0.57) MMP2MMP13MEN1KMT2AALDH1A1
SCHEMBL26213665 0.80 ABCB1 (0.39) TSHR
SCHEMBL4960132 0.77 USP30 (0.57) USP30MMP2MMP13USP5CARM1
SCHEMBL26213661 0.76 HSD11B1 (0.52) USP30MMP2MMP13USP5MMP3
SCHEMBL26213669 0.75 HCAR2 (0.37) —
SCHEMBL4960919 0.73 CA12 (0.54) USP30MMP2MMP13USP5MMP3
SCHEMBL27582496 0.72 MMP2 (0.52) USP30MMP2MMP13USP5MMP3
SCHEMBL31527727 0.72 CA12 (0.56) USP30MMP2MMP13USP5MMP3
SCHEMBL4964431 0.72 MMP2 (0.54) USP30MMP2MMP13USP5MMP3
SCHEMBL21033833 0.72 HSD11B1 (0.51) USP30MMP2MMP13USP5MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2026-03-10 — — US disclosed
EP-4175718-B1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIV CLAUDE BERNARD LYON (FR) 2024-10-02 — — EP disclosed
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 — — CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 — — US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 — — US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 — — US disclosed
EP-4175718-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) 2023-05-10 — — EP disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 — — CN disclosed
WO-2022008475-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2022-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer CKS2, CSNK2A3, CSNK1A1L USP30 2031/4885MMP2 3170/4885MMP13 2452/4885
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 USP30 1108/4885MMP2 2564/4885MMP13 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback